1. Home
  2. VRTX vs MAR Comparison

VRTX vs MAR Comparison

Compare VRTX & MAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated

HOLD

Current Price

$426.38

Market Cap

115.7B

Sector

Technology

ML Signal

HOLD

Logo Marriott International

MAR

Marriott International

HOLD

Current Price

$361.02

Market Cap

94.9B

ML Signal

HOLD

Company Overview

Basic Information
Metric
VRTX
MAR
Founded
1989
1927
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Hotels/Resorts
Sector
Technology
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
115.7B
94.9B
IPO Year
2006
2005

Fundamental Metrics

Financial Performance
Metric
VRTX
MAR
Price
$426.38
$361.02
Analyst Decision
Buy
Buy
Analyst Count
29
16
Target Price
$539.69
$359.31
AVG Volume (30 Days)
981.5K
1.3M
Earning Date
05-04-2026
05-06-2026
Dividend Yield
N/A
0.76%
EPS Growth
836.54
14.17
EPS
4.02
9.51
Revenue
$2,488,652,000.00
$26,186,000,000.00
Revenue This Year
$10.79
$304.38
Revenue Next Year
$10.47
$5.38
P/E Ratio
$27.74
$37.29
Revenue Growth
46.20
4.33
52 Week Low
$362.50
$253.56
52 Week High
$509.98
$380.00

Technical Indicators

Market Signals
Indicator
VRTX
MAR
Relative Strength Index (RSI) 42.30 55.77
Support Level $403.16 $312.30
Resistance Level $428.73 $370.00
Average True Range (ATR) 8.32 8.66
MACD 0.22 -2.20
Stochastic Oscillator 46.12 49.45

Price Performance

Historical Comparison
VRTX
MAR

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

About MAR Marriott International

Marriott operates 1.8 million rooms across roughly 30 brands. At the end of 2025, luxury represented roughly 10% of total rooms, premium was 42%, select service was 46%, and midscale was 2%. Marriott, Courtyard, and Sheraton are the largest brands, while Autograph, Tribute, Moxy, Aloft, and Element are newer lifestyle brands. Managed and franchised represented 99% of total rooms as of Dec. 31, 2025. North America makes up 61% of total rooms. Managed, franchise, and incentive fees represent the vast majority of revenue and profitability for the company.

Share on Social Networks: